Search Results - apoptosis

3 Results

Sort By:

Synthetic Lethality of IR with ABBV-155 in Glioblastoma (GBM) (UCLA Case No. 2021-232)

UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered that irradiation therapy can be combined with an antibody drug conjugate to form a novel therapeutic strategy to treat and extend survival of glioblastoma patients. BACKGROUND: Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. The National Brain...

Published: 8/28/2024 | Inventor(s): David Nathanson

Keywords(s): Antibody-Drug Conjugate, Apoptosis, Brain cancer, Cancer, Glioblastoma, irradiation

Category(s): Therapeutics > Oncology

Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)

UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....

Published: 5/8/2024 | Inventor(s): Roger Lo

Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Targeting the Intrinsic Apoptotic Machinery in Glioblastoma Multiforme (GBM) (UCLA Case No. 2020-446)

UCLA researchers in the Department of Molecular and Medical Pharmacology identified the mechanisms of apoptotic resistance in glioblastoma multiforme (GBM) and developed a novel therapy to treat GBM. BACKGROUND: Glioblastoma (GBM) is the most aggressive form of brain tumor. Therapeutic options for GBM are limited and suboptimal. Treatment usually...

Published: 2/16/2024 | Inventor(s): David Nathanson

Keywords(s): anti-apoptotic inhibitor, Anti-apoptotic pathway, Apoptosis, Brain Tumor, Glioblastoma, irradiation, p53, temozolomide

Category(s): Therapeutics > Oncology